Confidence in the future with a strong organisation
A little more than three months have passed since our shares were listed on Nasdaq First North and, at Xintela, we are progressing with our development programs and our goals according to plan.
In April, we communicated that we had initiated a study on cartilage damage in horses in the US, with a planned read out at the end of the year. Our preclinical stem cell development in Germany is also progressing well. In parallel with these studies, we are evaluating the effect of our antibodies on the growth and survival of glioblastoma cells in both in vitro and animal models. Since our listing, we have strengthened our organisation with the recruitment of Caroline Ehrencrona as Director Clinical Development and Regulatory Affairs and Christer Betsholtz as scientific and strategic advisor in our cancer project. In addition, we are working to increase our international presence and have attended conferences in both Japan (cell therapy in cartilage damage) and Poland (brain tumours).
In this newsletter, Caroline Ehrencrona answers questions about her initial impressions of Xintela. We also cover our visit to Poland, an interesting scientific article on cancer research published by an American research group and about the communication of our patent portfolio.
I will take this opportunity to wish all our shareholders a wonderful summer and share my hopes of an exciting remainder of the year.
Kind regards,
Evy Lundgren-Åkerlund,
CEO, Xintela.
